Please login to the form below

Not currently logged in
Email:
Password:

Biocon in drug development talks with Bayer

According to a report in the Indian newspaper, The Economic Times, biotechnology company, Biocon, is in discussions with German pharmaceutical company Bayer regarding the co-development of biotechnology drugs.

According to a report in the Indian newspaper, The Economic Times, biotechnology company, Biocon, is in discussions with German pharmaceutical company Bayer regarding the co-development of biotechnology drugs.

Biocon's managing director and chairman, Kiran Mazumdar-Shaw, told the newspaper that the agreement, which initially involved research activities, could also include biotech drug development activities.

Biocon, which has not commented on the report, derives much of its revenue from ethical drugs, such as head and neck cancer treatment, BioMab EGFR, as well as its enzyme business. The firm's strategy is to increase the share of research services business to a quarter of its total revenue in the next five years from about 15 per cent currently.

Bristol-Myers Squibb (BMS) revealed back in March 2007 that it was to partner with Biocon's research services unit, Sungene, and set up a facility in Bangalore to aid discovery and early drug development.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics